EIX
69
7
DD
60
-7
CL
50
3
PYPL
52
2
RIG
58
-2
HCP
76
2
MCD
60
6
ESS
65
5
LH
50
2
HIG
64
5
NWSA
97
8
PSX
42
2
MTB
67
2
MAS
62
4
NWS
83
4
FMC
41
-3
TSN
42
4
XYL
41
4
PHM
63
4
PVH
65
-3
EIX
69
7
DD
60
-7
CL
50
3
PYPL
52
2
RIG
58
-2
HCP
76
2
MCD
60
6
ESS
65
5
LH
50
2
HIG
64
5
NWSA
97
8
PSX
42
2
MTB
67
2
MAS
62
4
NWS
83
4
FMC
41
-3
TSN
42
4
XYL
41
4
PHM
63
4
PVH
65
-3
Financhill
Back

Nebius Group NV 10K Form

Sell
30

NBIS
Nebius Group NV

Last Price:
19.92
Seasonality Move:
-2.07%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NBIS News And Ratings

See the #1 stock for the next 7 days that we like better than NBIS

NBIS Financial Statistics

Sales & Book Value

Annual Sales: $9.04B
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $14.42
Price / Book: 1.4

Profitability

EPS (TTM): -0.63500
Net Income (TTM): $-155.45M
Gross Margin: $4.97B
Return on Equity: -4.57%
Return on Assets: -2.41%

Nebius Group NV Earnings Forecast

Key Nebius Group NV Financial Ratios

  • The Gross Profit Margin over the past 4 years for NBIS is 55.00%.
  • The Selling, General & Administrative Expenses for NBIS have been equal to 33.44% of Gross Profit Margin.
  • The Research & Development expenses have been 12.87% of Revenue.
  • The Interest Expense is 54.67% of Operating Income.
  • The Net Earning history of NBIS is 2.48% of Total Revenues.
  • Per Share Earnings over the last 4 years have been positive in 1 years.

Nebius Group NV Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Interactive Media & Services
Sector: Communication Services
Current Symbol: NBIS
Website: group.nebius.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 22.24
Quick Ratio: 21.85

Price-to-Earnings

Trailing P/E Ratio: 33.1
Forward P/E Ratio: 0

NBIS Technical Analysis vs Fundamental Analysis

Sell
30
Nebius Group NV (NBIS) is a Sell

Is Nebius Group NV a Buy or a Sell?

  • Nebius Group NV stock is rated a Sell
    The current Nebius Group NV [NBIS] share price is $19.92. The Score for NBIS is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.